CN101060846A - 采用可用于注射的β－内酰胺酶抑制剂防止β－内酰胺酶介导抗生素抗性的成分 - Google Patents

采用可用于注射的β－内酰胺酶抑制剂防止β－内酰胺酶介导抗生素抗性的成分 Download PDF

Info

Publication number
CN101060846A
CN101060846A CNA2005800395645A CN200580039564A CN101060846A CN 101060846 A CN101060846 A CN 101060846A CN A2005800395645 A CNA2005800395645 A CN A2005800395645A CN 200580039564 A CN200580039564 A CN 200580039564A CN 101060846 A CN101060846 A CN 101060846A
Authority
CN
China
Prior art keywords
sodium
composition
sulbactam
ceftriaxone
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800395645A
Other languages
English (en)
Chinese (zh)
Inventor
M·乔杜里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Venus Remedies Ltd
Original Assignee
Venus Remedies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venus Remedies Ltd filed Critical Venus Remedies Ltd
Publication of CN101060846A publication Critical patent/CN101060846A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CNA2005800395645A 2004-12-02 2005-11-28 采用可用于注射的β－内酰胺酶抑制剂防止β－内酰胺酶介导抗生素抗性的成分 Pending CN101060846A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2411/DEL/2004 2004-12-02
IN2411DE2004 2004-12-02

Publications (1)

Publication Number Publication Date
CN101060846A true CN101060846A (zh) 2007-10-24

Family

ID=35789266

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800395645A Pending CN101060846A (zh) 2004-12-02 2005-11-28 采用可用于注射的β－内酰胺酶抑制剂防止β－内酰胺酶介导抗生素抗性的成分

Country Status (23)

Country Link
US (2) US8273732B2 (enExample)
EP (1) EP1841432B1 (enExample)
JP (1) JP5269415B2 (enExample)
KR (2) KR20070067189A (enExample)
CN (1) CN101060846A (enExample)
AT (1) ATE476981T1 (enExample)
AU (1) AU2005310888B2 (enExample)
BR (1) BRPI0517128A (enExample)
CY (1) CY1110886T1 (enExample)
DE (1) DE602005022939D1 (enExample)
DK (1) DK1841432T3 (enExample)
ES (1) ES2349301T3 (enExample)
HR (1) HRP20100591T1 (enExample)
MX (1) MX2007006540A (enExample)
NZ (1) NZ555075A (enExample)
PL (1) PL1841432T3 (enExample)
PT (1) PT1841432E (enExample)
RS (1) RS51506B (enExample)
RU (1) RU2397768C2 (enExample)
SI (1) SI1841432T1 (enExample)
UA (1) UA91204C2 (enExample)
WO (1) WO2006059344A1 (enExample)
ZA (1) ZA200704394B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822147A (zh) * 2016-11-03 2017-06-13 湘北威尔曼制药股份有限公司 一种头孢曲松钠和舒巴坦钠组合物、包含该组合物的药物制剂及其应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030010176A (ko) * 2001-07-25 2003-02-05 이병두 은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
JP5639471B2 (ja) * 2008-07-28 2014-12-10 惠三 山口 感染症治療効果増強剤
CN101537009B (zh) * 2009-04-30 2010-09-15 海口奇力制药股份有限公司 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
PL2714034T3 (pl) * 2011-05-28 2018-12-31 Wockhardt Limited Kompozycje zawierające cefepim i tazobaktam
MX362683B (es) * 2011-07-26 2019-01-31 Wockhardt Ltd Composiciones farmacéuticas que comprenden antibiótico de beta-lactama, sulbactama e inhibidor de beta-lactamasa.
WO2013042140A2 (en) * 2011-09-23 2013-03-28 Manu Chaudhary Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
BR112014023402B1 (pt) 2012-03-26 2020-09-29 Santen Pharmaceutical Co., Ltd Solução oftálmica compreendendo diquafosol e métodos para produção da mesma, para inibição da formação dos precipitados insolúveis na mesma, para redução da irritação ocular causada pela mesma e para aumentar a eficácia de conservação da mesma
MX365321B (es) 2012-06-07 2019-05-29 Los Angeles Childrens Hospital Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
WO2014052799A1 (en) * 2012-09-27 2014-04-03 Cubist Pharmaceuticals, Inc. Tazobactam arginine antibiotic compositions
AU2015219038B2 (en) 2014-02-18 2018-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
EP3125887A1 (en) * 2014-03-29 2017-02-08 Wockhardt Limited Pharmaceutical compositions comprising cefepime or sulbactam
CA2914314C (en) * 2014-04-03 2021-05-18 Baxter International Incorporated Injection bag and injection preparation assembly
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
US10668079B2 (en) 2016-11-02 2020-06-02 Xiangbei Welman Pharmaceutical Co., Ltd. Composition composed of ceftriaxone sodium and sulbactum sodium
RU2665006C1 (ru) * 2017-02-28 2018-08-24 Общество с ограниченной ответственностью "Супербаг Солюшенс" Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения
KR102790878B1 (ko) 2018-08-09 2025-04-02 앤타바이오 에스에이에스 세린 베타-락타마제의 억제제로서 다이아자바이사이클로옥타논
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
KR20230121863A (ko) 2020-12-17 2023-08-21 아이덱스 래보러토리즈, 인코포레이티드 로키산 홍반열 검출 및 치료
WO2025165952A1 (en) * 2024-01-31 2025-08-07 The Penn State Research Foundation Process for reduction of drug-resistant bacteria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630510B1 (en) * 1999-10-28 2003-10-07 Merck & Co., Inc. Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
ES2298672T3 (es) * 2003-04-14 2008-05-16 Wyeth Holdings Corporation Composiciones que contienen piperacilina y tazobactam utiles para inyeccion.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822147A (zh) * 2016-11-03 2017-06-13 湘北威尔曼制药股份有限公司 一种头孢曲松钠和舒巴坦钠组合物、包含该组合物的药物制剂及其应用

Also Published As

Publication number Publication date
AU2005310888A1 (en) 2006-06-08
JP5269415B2 (ja) 2013-08-21
WO2006059344B1 (en) 2006-11-02
HRP20100591T1 (hr) 2010-12-31
ES2349301T3 (es) 2010-12-29
RS51506B (sr) 2011-06-30
KR20090101514A (ko) 2009-09-28
SI1841432T1 (sl) 2011-02-28
RU2007124325A (ru) 2009-01-10
JP2008521884A (ja) 2008-06-26
EP1841432B1 (en) 2010-08-11
CY1110886T1 (el) 2015-06-10
RU2397768C2 (ru) 2010-08-27
WO2006059344A1 (en) 2006-06-08
DK1841432T3 (da) 2010-12-06
US9012442B2 (en) 2015-04-21
AU2005310888B2 (en) 2011-01-06
ATE476981T1 (de) 2010-08-15
KR101244362B1 (ko) 2013-03-18
MX2007006540A (es) 2008-01-31
PT1841432E (pt) 2010-10-25
KR20070067189A (ko) 2007-06-27
NZ555075A (en) 2011-02-25
US8273732B2 (en) 2012-09-25
BRPI0517128A (pt) 2008-09-30
ZA200704394B (en) 2008-09-25
US20130023512A1 (en) 2013-01-24
PL1841432T3 (pl) 2011-01-31
EP1841432A1 (en) 2007-10-10
UA91204C2 (ru) 2010-07-12
US20100160277A1 (en) 2010-06-24
DE602005022939D1 (de) 2010-09-23

Similar Documents

Publication Publication Date Title
US9012442B2 (en) Compositions for combating beta-lactamase-medicated antibiotic resistance using beta-lactamase inhibitors useful for injection
CN1289084C (zh) 药物制剂
CN103648496B (zh) 包含β-内酰胺抗生素、舒巴坦和β-内酰胺酶抑制剂的药物组合物
US20200093814A1 (en) Combination therapy with amidine substituted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic resistant bacterial strains
US10561675B2 (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN101080221A (zh) 抗药性细菌感染疾病的肠胃外综合治疗
CN101076342A (zh) 用于对治疗感染提供总解决方案的抗生素组合
AU2013308128B2 (en) Antibacterial compositions
CN101080230A (zh) 包括囊性纤维化的严重感染的治疗和控制
CN1565457A (zh) 一种抑制β－内酰胺酶的抗菌组合药物
WO2019126910A1 (zh) 含有哌拉西林的组合物、其药物制剂及其应用
EP2934524B1 (en) Penethamate veterinary injectable formulations
CN1582942A (zh) 头孢呋辛钠复方制剂
CN1485035A (zh) 一种美洛西林的抗菌组合药物
CN1526397A (zh) 一种抑制β-内酰胺酶的抗菌组合药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071024